Explorers led the strongest gains, while biotech, payments and gold producers suffered the biggest falls. Takeover bids, project funding and trial results drove sharp moves across the market.
Resources stayed busy, but investors punished companies with weak cash positions, delayed approvals or disappointing operating updates.
- Western Mines Group (ASX:WMG) surged 34.78% after lifting its Mulga Tank nickel resource to 7.2 million tonnes of contained nickel.
- 4DMedical (ASX:4DX) fell 33.51% despite record scans and rising revenue, showing that strong operating growth did not satisfy investors.
- OFX Group (ASX:OFX) dropped 17.65% after Equals failed to confirm its proposed $1.00 takeover by the deadline.
- Catalyst Metals (ASX:CYL) and Elixir Energy (ASX:EXR) also fell sharply as gold production was delayed and gas project funding remained conditional.
- Takeover activity continued around Ingenia Communities (ASX:INA), Global Lithium (ASX:GL1) and Challenger (ASX:CGF).
Western Mines Group (ASX:WMG) was the week’s biggest percentage winner, rising 34.78% after reporting 7.2 million tonnes of contained nickel at Mulga Tank. 4DMedical (ASX:4DX) was the biggest faller, dropping 33.51% even as scans rose 61% and quarterly revenue increased 66%. OFX Group (ASX:OFX) fell 17.65% after Equals missed the deadline to confirm its $1.00 takeover offer.
Resources lead, but size is not value
WMG’s gain followed a large resource increase at Mulga Tank. The estimate now contains 7.2 million tonnes of nickel. Investors still need proof that the low-grade material can support a profitable mine. A future study will test mining and processing costs.
Other resource companies also posted strong technical news. Turaco Gold (ASX:TCG) raised A$120 million to buy the remaining 20% of its Afema project. Aurum Resources (ASX:AUE) lifted Boundiali’s resource to 3.84 million ounces. FireFly Metals (ASX:FFM) reported a A$3.0 billion study for Green Bay. These figures may attract buyers, but each project still needs permits, funding and further studies.
Takeovers keep changing the price story
Ingenia Communities (ASX:INA) drew competing proposals. AVID offered $5.35 per security, then Warburg Pincus raised its offer to $5.45. Investors may receive up to another five cents through a permitted distribution. Neither proposal is binding, and Ingenia still supports its proposed Peet transaction. The price rose strongly after reopening, but the later move was smaller. That suggests some early buying has faded while investors wait for a firm offer.
Global Lithium (ASX:GL1) also remains tied to a cash takeover. Titan’s $1.15-per-share proposal values the company at about A$333 million. The offer arrived after a study lifted Manna’s estimated value and cut the money needed before production. Shareholders still face approval, funding and construction conditions. Challenger (ASX:CGF) kept talks open with TAL over an $11.80 proposal, but its board has not recommended the offer.
Clinical failures and cash pressure hurt smaller companies
Biotech investors faced several setbacks. Paradigm Biopharmaceuticals (ASX:PAR) stopped its key knee arthritis trial after the results fell below the level needed to continue. The company is now in voluntary administration with A$4.33 million in cash. Chimeric Therapeutics (ASX:CHM) halted its CAR-T cancer trial after the highest dose caused safety problems. It had only $1.35 million in cash.
Immutep (ASX:IMM) also suffered from a failed lung cancer trial. Its loss widened to A$79.3 million, and manufacturing problems remain under review. The company has A$68.9 million in cash and term deposits. OncoSil Medical (ASX:OSL) gained US approval for its cancer device, but its cash balance supports less than three quarters at the reported spending rate. Approval can help sales, but reimbursement and the small first launch remain important tests.
Projects need more than good numbers
Several companies reported attractive project studies, but the next step is harder. Sky Metals (ASX:SKY) outlined a A$438 million pre-tax value for Tallebung. Pivotal Metals (ASX:PVT) reported a A$920 million post-tax value for Horden Lake. Ark Mines (ASX:AHK) put an A$883 million post-tax value on Sandy Mitchell. These are study estimates, not operating mines. They depend on metal prices, permits, construction costs and new capital.
Funding concerns drove several falls. Catalyst Metals (ASX:CYL) cut its FY27 gold guidance after moving Trident and Old Highway output into FY28. Elixir Energy (ASX:EXR) reported a strong early gas flow, but the stock still fell 17.39%. Investors appear to have focused on the need to complete the Beach Energy farmout and confirm later well performance. Canyon Resources (ASX:CAY) withdrew its first-shipment target after a bank paused further project loan payments.
Some companies showed the opposite pattern. Bannerman Energy (ASX:BMN) secured funding and approved construction at Etango. Lynas Rare Earths (ASX:LYC) reported record quarterly revenue and neodymium-praseodymium production. Capricorn Metals (ASX:CMM) kept its gold guidance after completing the Karlawinda expansion. Their next challenge is turning construction and production plans into reliable cash returns.
Bottom Line?
The next week should bring attention to takeover negotiations at Ingenia and Global Lithium, the court process affecting European Lithium’s merger, and project funding decisions across mining and biotechnology. Investors will also watch whether delayed production dates at Catalyst and Canyon lead to further changes in company plans.
Questions in the middle?
- Will Ingenia Communities receive a binding offer above Warburg Pincus’s $5.45 proposal, or will the Peet transaction continue?
- Can small biotechnology companies such as Paradigm and Chimeric secure a restructuring or new funding after their trial setbacks?
- Will projects with large study values, including Green Bay, Sandy Mitchell and Tallebung, secure the money and approvals needed to move forward?
Sources
This wrap draws on announcements from 26 companies. For the full story and each verified source, see the company's own article:
ASX:4DX, ASX:AHK, ASX:AUE, ASX:BMN, ASX:BOT, ASX:CAY, ASX:CGF, ASX:CHM, ASX:CMM, ASX:CYL, ASX:DGR, ASX:EXR, ASX:FFM, ASX:GL1, ASX:IMM, ASX:INA, ASX:IPX, ASX:KAN, ASX:LYC, ASX:OFX, ASX:OSL, ASX:PAR, ASX:PVT, ASX:SKY, ASX:TCG, ASX:WMG